Ibrutinib Plus R-CHOP Shows Treatment Promise for Diffuse Large B-Cell Lymphoma

Phase IB study findings pave the way for a phase III trial of the Bruton’s Tyrosine kinase inhibitor ibrutinib with a standard R-CHOP regimen for diffuse large B-cell lymphoma treatment...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.